drugset / Trial / NCT00442351

Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)

NCT00442351 ↗

Phase 4 Terminated 26 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with "Asmanex" Placebo QD PM for 12 weeks. Efficacy will be measured for the changes in forced expiratory volume in 1 second (FEV1) from baseline to the end of treatment period (Week 12 or end of the study).

Timeline

Start
2006-09
Primary completion
2007-04
Completion
2007-04

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Asmanex Twisthaler Unknown 220 ug Inhaled

Indications